Chitosan caged liposomes for improving oral bioavailability of rivaroxaban: in vitro and in vivo evaluation

• Published in: Pharmaceutical development and technology Vol. 26; no. 3; pp. 316 - 327
• Main Authors: Elsayad, Maged K., Mowafy, Hammam A., Zaky, Alaa A, Samy, Ahmed M.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 16.03.2021
• Subjects: chitosan-coated liposomes; flexible liposomes; Rivaroxaban; chitosan-coated liposomes; Rivaroxaban; flexible liposomes
• ISSN: 1083-7450; 1097-9867
• DOI: 10.1080/10837450.2020.1870237

In this study, chitosan (CS) caged classic liposomes (CLs) and flexible liposomes (FLs) were developed to enhance the oral bioavailability of rivaroxaban (RVX) in the fasted condition. The prepared formulations were subjected to physicochemical characterization included: FTIR, DSC, zeta potential, particle size, polydispersity index, entrapment efficiency, in vitro dissolution, and transmission electron microscope imaging. The selected formulation (RVX-TFL2) composed of PL S100/Tween 80 (85/15% w/w) and coated with CS solution in the strength of (0.2% w/v) had a particle size of 105.67 nm, a zeta potential of +5.67 mV and EE of 96.07%. Compared to RXV suspension, the pharmacokinetic parameters (C max , AUC 0-24 , and AUC 0-∞ ) of RVX-TFL2 showed no statistically significant difference (P > 0.05) in the fasted and fed test animals. Besides, RVX bioavailability with RVX-TFL2 was improved by 59.66% and 26.97% in the fed and fasted states, respectively, compared to RVX suspension in the fed state. The result highlighted the efficacy of the prepared liquid formulation comprising CS coated liposomes in improving the oral bioavailability of RVX regardless of the fed state. Moreover, the studied liquid formulation could be utilized in developing a liquid dosage form that might be useful as a pediatric formulation of RVX.